Introduction to discussion papers on draft FDA guidance on adaptive designs
- PMID: 21058106
- DOI: 10.1080/10543406.2010.514448
Introduction to discussion papers on draft FDA guidance on adaptive designs
Similar articles
-
Comments on the FDA draft guidance on adaptive designs.J Biopharm Stat. 2010 Nov;20(6):1166-70. doi: 10.1080/10543406.2010.514458. J Biopharm Stat. 2010. PMID: 21058112 No abstract available.
-
FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.J Biopharm Stat. 2010 Nov;20(6):1143-9. doi: 10.1080/10543406.2010.514456. J Biopharm Stat. 2010. PMID: 21058110
-
On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.J Biopharm Stat. 2010 Nov;20(6):1171-7. doi: 10.1080/10543406.2010.514460. J Biopharm Stat. 2010. PMID: 21058113
-
Review of draft FDA adaptive design guidance.J Biopharm Stat. 2010 Nov;20(6):1132-42. doi: 10.1080/10543406.2010.514455. J Biopharm Stat. 2010. PMID: 21058109 Review.
-
Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.Eur J Cancer. 2009 Feb;45(3):347-53. doi: 10.1016/j.ejca.2008.09.032. Epub 2008 Nov 14. Eur J Cancer. 2009. PMID: 19013787 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical